The Global Pharmaceutical Lipids Industry is on the brink of a remarkable growth journey, as revealed by Future Market Insights (FMI). According to FMI’s latest analysis, the market is set to experience a significant upswing during the forecast period, with an average Compound Annual Growth Rate (CAGR) of 5.0%.
In 2023, the Global Pharmaceutical Lipids Industry is projected to generate sales totaling $4.93 billion, marking a substantial leap in its value. Fast forward to 2033, and the market is predicted to reach a staggering value of $8.04 billion, illustrating its substantial potential for expansion.
This forecast is a substantial leap from the market’s value of $4.44 billion in 2021, as per FMI’s previous market analysis. The Global Pharmaceutical Lipids Industry has displayed consistent growth, driven by a robust 5.1% CAGR, and is anticipated to achieve a value of $7.70 billion by 2032.
Request a Sample of this Report Now!
https://www.futuremarketinsights.com/reports/sample/rep-gb-10983
Furthermore, efforts by governments and regulatory agencies in developed nations, such as the U.S. and the U.K., to streamline the approval process for excipients, are expected to push sales in the market. Because of their cost-effectiveness and patient compliance, oral solid dosage forms are the dominant mode of delivery in the Global Pharmaceutical Lipids Industry and are the preferred option for many pharmaceutical products.
The use of capsules or tablets for drug delivery provides advantages such as increased physical and chemical stability, ease of handling, distinct brand recognition based on color and shape, and controlled-release options. The majority of liposomal drugs are derived from oral solid drug formulations. The ease of use among patients, particularly children, is expected to boost sales of oral drugs, which will have a direct impact on pharmaceutical lipid sales.
For example, conventional hard solid tablets are difficult to swallow for approximately 50% of patients. This has prompted pharmaceutical companies to create more innovative solid oral product forms, such as effervescent tablets, orally disintegrating granules (ODGs), lozenges, chewable tablets, and instant drinks. This is expected to generate significant demand for liposomal excipients during the forecast period, boosting market growth.
“Increasing investments in contract manufacturing of pharmaceutical lipids, along with growing demand for oral solid drug formulation is expected to augment the growth in the market over the forecast period,” says Sabyasachi Ghosh (Associate Vice President at Future Market Insights, Inc.)
Key Takeaways:
- Triglyceride sales are expected to account for more than 44.3% of the market by 2032, rising at a 5.1% CAGR during the forecast period.
- By form, the semi-solid segment commands more than 60.0% of the market in 2021 and is expected to account for 62.7% of the total market share by 2032.
- In terms of source, sales of semi-synthetic sources will increase at a 5.8% CAGR.
- In 2021, applications in the conventional lipid-based drug delivery systems (LBDDS) segment held a commanding 64.4% share.
- The most widely used route of administration will be oral pharmaceutical lipids. In 2021, the segment held 40.8% of the total market share.
- The U.S. will continue dominating the North America pharmaceutical lipids market over the forecast period owing to the presence of a robust healthcare sector.
- Demand in the U.K. pharmaceutical lipids market will surge at a 5.1% CAGR over the assessment period.
- Sales in the India market are slated to increase at a 5.2% CAGR, accounting for a lion’s share in the South Asia pharmaceutical lipids market.
Exploring the study’s key assumptions. Ask An Analyst!
https://www.futuremarketinsights.com/ask-the-analyst/rep-gb-10983
Competition Landscape
Acquisitions, mergers, expansion, development of an extensive clinical pipeline, and product launches are the key strategies adopted by manufacturers to increase the consumer base in various countries. For instance:
- In July 2020, ABITEC announced the acquisition of Larodan AB, a manufacturer and international marketer of state-of-the-art, high-purity research-grade lipids. The acquisition expanded ABITEC’s functional lipid product offerings and scientific capabilities to better serve the pharmaceutical, nutritional, and industrial markets.
- In January 2020, BASF completed the acquisition of the polyamide business of Solvay.
- In July 2020, Croda International Plc announced the acquisition of Avanti Polar Lipids, Inc., a knowledge-intensive leader in lipid-based drug delivery technologies for the next generation of pharmaceuticals.
Key Companies Profiled
- ABITEC Corporation (ABF Ingredients)
- BASF SE
- Croda International Plc
- Corden Pharma
- NOF (Nippon Oil & Fats) Corporation
- Cayman Chemical Company
- Lipoid GmbH
Get Your Customized Impactful Report Now!
https://www.futuremarketinsights.com/customization-available/rep-gb-10983
Key Market Segments Covered in Global Pharmaceutical Lipids Industry Research
By Product:
- Triglycerides
- Phospholipids
- Sphingolipids
- Cholesterol
- Fatty Acids
- Others
By Source:
- Synthetic
- Semi-synthetic
- Natural
By Form:
- Liquid
- Semi-solid
- Solid
By Application:
- Conventional Lipid-based Drug Delivery Systems
- Self-Emulsifying Drug Delivery Systems
- Self-Microemulsifying Drug Delivery Systems
- Liposomes
- Solid Lipid Nanoparticles
- Nanostructured Lipid Carriers
- Others
By Route of Administration:
- Oral
- Tablet
- Solution
- Parenteral
- Intravenous
- Intramuscular (Vaccines)
- Topical
Click Here To Buy Your Full Report!
https://www.futuremarketinsights.com/checkout/10983
Author
Sabyasachi Ghosh (Associate Vice President at Future Market Insights, Inc.) holds over 12 years of experience in the Healthcare, Medical Devices, and Pharmaceutical industries. His curious and analytical nature helped him shape his career as a researcher.
Identifying key challenges faced by clients and devising robust, hypothesis-based solutions to empower them with strategic decision-making capabilities come naturally to him. His primary expertise lies in Market Entry and Expansion Strategy, Feasibility Studies, Competitive Intelligence, and Strategic Transformation.
Holding a degree in Microbiology, Sabyasachi has authored numerous publications and has been cited in journals, including The Journal of mHealth, ITN Online, and Spinal Surgery News.
About Future Market Insights (FMI)
Future Market Insights, Inc. (ESOMAR certified, recipient of the Stevie Award, and a member of the Greater New York Chamber of Commerce) offers profound insights into the driving factors that are boosting demand in the market. FMI stands as the leading global provider of market intelligence, advisory services, consulting, and events for the Packaging, Food and Beverage, Consumer Technology, Healthcare, Industrial, and Chemicals markets. With a vast team of over 5,000 analysts worldwide, FMI provides global, regional, and local expertise on diverse domains and industry trends across more than 110 countries.
Contact Us:
Future Market Insights Inc.
Christiana Corporate, 200 Continental Drive,
Suite 401, Newark, Delaware – 19713, USA
T: +1-845-579-5705
For Sales Enquiries: sales@futuremarketinsights.com
Website: https://www.futuremarketinsights.com
LinkedIn| Twitter| Blogs | YouTube